The app allows practices to submit results along with cytology and histopathology results in order to help train the AI algorithm and improve its accuracy from an original sensitivity of 85% and negative predictive value of 97%.
Liron Levy-Hirsch, Managing Director of HT Vista, said: “The HT app has provided us with over 700 additional validated scans to analyse this year alone.
"The validation process is well controlled, whereby we use the lab results to tag the scans as benign or malignant and let the algorithm know if it was correct or not.
"The more we train the algorithm the more accurate it becomes, and it is extremely exciting to see the sensitivity increase to 90% and the NPV to 98%.”
HT Vista says the app was developed to meet demand from clinics.
Liron said: "By having a portal to upload lab results alongside the device’s results not only do we further improve the device, but we also increase confidence among our vets and nurses that the device is a reliable tool.
https://ht-vista.uk
The gallery was traditionally held in-person at the NAVC’s annual Veterinary Expo & Meeting (VMX) in Florida.
Now, for the first time since it began in 2012, the gallery is accessible to everyone everywhere months before the live event in June.
The new Virtual VMX New Product Gallery went live this week and will run until 3rd September 2021. It showcases 21 new product innovations from the following companies: BioNote; Boehringer Ingelheim Animal Health; Dechra Veterinary Products; Epicur Pharma; GVL; Hill’s Pet Nutrition, Inc.; Merck Animal Health; Neogen Corporation; Ogena Solutions; Purina; Royal Canin; Vetoquinol; Zoetis Petcare.
NAVC CEO Gene O’Neill said: "Each year, NAVC’s panel of experts select the most innovative new products and services to be showcased as part of the VMX Expo. We are excited to take this VMX staple and, for the first time, make it universally available to members of our global veterinary community everywhere.
"And they don’t have to wait until June to learn about and try these important new products. The VMX Virtual New Product Gallery launch is part of the NAVC’s expanding virtual portfolio which breaks down barriers of geography and time to make the best products the veterinary industry has to offer available to veterinary professionals worldwide.” The gallery is free to access. You can register here: https://vmxvirtual.simexpo.com/page/100
XLVets has called on experts in people development, legal, IT and HR, as well as its practice owners, managers and team leaders to develop a package of coronavirus resources. The package includes guidance and best practice, tips offered by XLVets members, expert guidance in the use of technology to support home workers, access to the XLVets Thriving in Practice wellbeing initiative and more.
To access the resources at www.xlvets.co.uk without charge or obligation, email admin@xlvets.co.uk.
Colm McGinn (pictured right), from XLVets said: "We are very good at working together to develop solutions for problems and supporting each other. This is a national challenge and while our members have faced some difficult decisions, they've been able to share that decision-making process with their peers, calling on them for ideas, guidance and support.
"It's a big ask for just one or two partners to interpret the guidance in a rapidly changing environment and to stay informed about advice from regulatory bodies and associations. We've all benefited from sharing knowledge and it's lifted some of the pressure that comes from taking individual action, while still having freedom to do what's right for your own practice and people. I can't think of a better time for us to share our learning and resources for the greater good."
For more information, visit: https://www.xlvets.co.uk/the-boss.
The Walpole Bay Tidal Pool is the biggest in the UK, covering four acres.
Everyone taking part is being challenged to raise at least £100 for Vetlife, to go towards its helpline, health support and financial support for the veterinary community.
Sea temperature at this time of year is a decidedly brisk 10 degrees Celsius, but Vetlife says the dress code is reasonably relaxed: anything from a swimming costume to a full diving dry suit!
https://events.more-human.co.uk/event/1713190086537x259173669533122560
Founded in 2005 by Jane Howorth MBE, the British Hen Welfare Trust rehomes commercial laying hens that would usually be sent to slaughter, typically at 18 months.
The charity has rehomed hens in schools, community areas, prisons and back gardens around the country, where they have plenty of life left both as egg layers and companions.
The millionth hen, named Henrietta by His Majesty, was rehomed at Highgrove Gardens in Gloucestershire, along with 30 others earlier this month.
Jane said: “We’re thrilled that one million hens have been adopted and extremely pleased that Henrietta and her 30 feathered friends are heading to Highgrove Gardens.
"Helping a lorry load of 4,000 was my original target and we’ve exceeded my expectations by some margin!
"To think that so many hens have had a happy retirement gives me a great deal of pleasure as I’m sure it has for all the kind-hearted British supporters who’ve taken these deserving little creatures into their homes and hearts.
"From the day I started this charity, it’s been a privilege to meet and work with people who want to help hens and to work alongside the egg industry to champion hen welfare and free range eggs.”
www.bhwt.org.uk/one-millionth-hen.
The original TATE elbow replacement was first in clinical use in the 2010s and the revised 3rd generation version is apparently a much-improved implant, something which the clinical evaluation trial should demonstrate.
Andy Moores, head of the joint replacement programme at The Moores Orthopaedic Clinic, said: “Canine elbow replacement can be a game-changer for dogs living with chronic elbow pain but up until this point the elbow replacement systems have not been as reliable as we would like.
"The third-generation TATE implant has been in use with a small number of US surgeons for several years now and the results so far have been very promising.
"We are delighted that Biomedtrix have invited us to join the evaluation trial for this implant and that the RCVS Ethics Review Panel have approved this.
"We look forward to offering this surgery as an option for some of our most painful canine patients.”
www.mooresortho.com
Available in packs of 56 (4 x 14 tablet blister packs), Lodisure tablets are divisible for accurate dosing.
The recommended starting dose is 0.125-0.25 mg amlodipine per kg bodyweight per day, which equates to half a tablet for cats weighing less than 4kg (and more than 2kg) and one tablet per day for cats weighing between 4kg and 8kg.
It can be administered directly to the cat or given with a small quantity of food.
Dechra companion animal brand manager, Sarah Musgrave, said: “Feline hypertension is very often part of a more complex diagnosis, therefore it is important that antihypertensive therapies are easy to dose and administer.
"Lodisure is a new, first-line, easy to dose and administer treatment to control systolic blood pressure in cats while the underlying primary cause is diagnosed and treated, which vets can rely on in their day-to-day practice.”
https://www.dechra.co.uk/products/cat/prescription/lodisure.
The company says that Daxocox achieves significant improvement of clinical signs associated with the pain of osteoarthritis (OA) in dogs1,2 and also helps reduce the risk of breakthrough pain.
Breakthrough pain is defined as “an abrupt, short-lived, and intense pain that breaks through the analgesia that controls pain”3. Risk factors for breakthrough pain in cases of canine OA include poor owner compliance, variable plasma drug levels between doses, natural or exercise induced flare-ups and disease progression.
According to research carried out by the company, veterinary surgeons estimate that nearly half of their canine OA cases on daily NSAIDs experience breakthrough pain4, whilst owners put the figure much higher at 80%5.
Animalcare says that as well as compromising patient welfare and increasing the risk of clinical consequences such as wind-up pain (hypersensitisation), breakthrough pain risks owners losing confidence in their vet and/or the recommended treatment plan for their dog. This may lead owners to independently stray from the treatment plan, with potentially damaging consequences. In its research, 87% of vets agreed that avoiding breakthrough pain is critical to the management of canine OA4.
Animalcare adds that because of the pharmacology, there is no risk of risk of over-accumulation or need for mandatory treatment ‘breaks’6. Also, adverse effects were found to be no different from any other NSAID1,2 and there was no increase in treatment-related adverse effects at up to 5 times the recommended dose7, so Daxocox has a broad margin of safety and is well tolerated by dogs7.
James Beaumont, marketing manager at Animalcare said: “Daxocox’s weekly administration of a flavoured tablet addresses some of the challenges of managing canine OA that I’m certain most vets will identify with. Breakthrough pain is a real problem and by being able to provide consistent pain control, in a compliance friendly formulation, Daxocox is a real game changer for canine OA management.
For more information, visit: www.animalcare.co.uk, or contact your local Animalcare territory manager, or Animalcare’s head office on 01904 487687.
References:
Faecal calprotectin is a calcium-binding protein released into the gut lumen predominantly by neutrophils, and to a lesser extent by monocytes and macrophages, during intestinal inflammation.
Its presence in faeces reflects the degree of neutrophilic infiltration in the gut mucosa, making it a useful biomarker for identifying intestinal inflammation.
Faecal calprotectin lateral flow testing is already used in human health and included in the NICE guidelines for the management of inflammatory bowel disease (IBD)1.
Determining the underlying cause of chronic diarrhoea, vomiting and weight loss in cats and dogs can be complex, often requiring invasive procedures such as endoscopy or biopsy - both of which carry cost, risk, and sometimes practical limitations in general practice.
GIQuest is designed to offer a non-invasive, rapid alternative to support clinical decision-making.
Carus says that whilst not a replacement for histopathology, faecal calprotectin concentrations have been shown to correlate with disease severity in dogs and cats, as measured by tools such as the Canine Chronic Enteropathy Clinical Activity Index (CCECAI).2
New data from the University of Bristol Vet School appears to confirm the test’s ability to differentiate dogs with histologically-confirmed inflammatory enteropathy from healthy controls with high sensitivity (94%) and specificity (96%) using a score threshold of 3mg/kg.2
Carus says the test also performed well in cats, distinguishing those with inflammatory enteropathy from healthy controls with a specificity of 100% and sensitivity of 92%.
In addition, the test detected elevated calprotectin levels consistent with inflammatory gastroenteropathy in 25% of dogs receiving oral NSAIDs, which highlights its potential not only in long-term monitoring but also early in treatment when GI side effects may first emerge.
Jolian Howell of Carus Animal Health said: “Faecal calprotectin testing can provide additional clarity in a range of clinical scenarios.
"It is particularly useful when diagnosing and managing suspected inflammatory enteropathy or food related reactions and for monitoring or screening for GI side effects of oral non-steroidal anti-inflammatories in long term OA therapy regimes.”
The Bristol study also showed that dogs with food-responsive enteropathy had a significant drop in calprotectin concentrations following dietary change, reinforcing the test’s role in tracking treatment response.
Georgie Louca, Veterinary Business Manager for Carus Animal Health, added: ”By providing a measurable, visual indicator of intestinal inflammation, GIQuest also helps support client communication and can improve compliance during treatment or dietary trials.”
GIQuest is designed for use in practice, including during consultations, delivering colour-coded results in 15 minutes.
GIQuest is now available to veterinary practices across the UK and can be ordered through veterinary wholesalers NVS, Covetrus and MWI.
https://carusanimalhealth.com/giquest
References
The award categories are:
Nominations are welcome from both BSAVA members and non-members.
Nominations close on 30th October 2024 and the winners will be announced on 16th January 2025.
The BSAVA awards ceremony will take place at the reinvented Congress and Expo 2025, taking place at Manchester Central in March.
https://www.bsava.com/awards.
Vet-AI's automated triage app offers instant advice to pet owners 24/7, early detection of health issues and advice as to whether they need to speak to a vet.
For the blinded test, which was conducted in April 2025, three UK veterinary surgeons reviewed the responses from Vet-AI, Gemini 2.0 and ChatGPT 4.0 to 48 simulated enquiries from owners.
The vets evaluated each on clinical accuracy, triage effectiveness and the subjective criteria of factuality, integrity, safety, empathy and readability.
Vet-AI’s Large Language Model (LLM) achieved an accuracy score of 81%, surpassing Gemini (69%) and ChatGPT (50%).
Vet-AI’s model also stopped triage at the correct point in 81% of cases according to the vets, compared with Gemini’s 75% and ChatGPT’s 56%.
Vet-AI’s tool also outperformed the leading LLMs on subjective measures, delivering more empathetic, thorough and factual responses to pet owners.
Samantha Webster, Chief Veterinary Officer at Vet-AI said: “These latest results are a significant milestone in the development of automated triage.
"We’re proving we can provide trustworthy online pet care by combining clinical and technical expertise.
"This tool can support the wider industry too, engaging more pet owners in the first step of vet care, ensuring their pets get the care they need - whether in practice or remotely.
"We know that an increasing percentage of the UK pet population is struggling to access veterinary care.
"Whilst AI will never replace a vet, the use of innovative technology can break down the barrier to access, leading to more pets getting the care they need, when they need it."
“With this level of clinical accuracy and technical innovation, we're helping to bring great pet care to more people. As well as helping to create more demand for vet services by making the triage of pets as accurate as possible,” said Paul Hallett, Vet-AI founder and exec chair.
https://www.vet-ai.com/automated-triage
The webinars will be available as live podcasts and will also be able to be viewed on demand on the Dechra Academy.
In the strangles webinar, Dave Rendle, Gayle Hallowell and Richard Newton will explore the current landscape of strangles control, focusing on the role of vaccination, testing and quarantine measures.
In the disease prevention webinar, Gayle Hallowell, Dave Rendle, Tamzin Furtado and others will give an insight into chronic disease management and preventative vaccination to improve uptake and optimise treatment outcomes.
Both webinars broadcast from 8pm GMT, with a live Q&A session from 8:45pm, finishing at 9:15pm.
https://membership.elearning.vet/Dechra-equine-medicine-series.
The authors say that whilst it has long been suspected that adverse drug reactions are under-reported, this study is the first to show the scale of the problem, using real data from veterinary clinical records.
For the study, researchers looked for electronic heath records within the Small Animal Veterinary Surveillance Network (SAVSNET) which contained “adverse drug reactions” and “side effects” in the free-text clinical narratives.
The results were then analysed to determine the suspected product, the seriousness and expectedness of the event, and whether the event had been reported to the Veterinary Medicines Directorate or Marketing Authorisation Holders.
Of the 827 cases of suspected adverse drug reactions identified out of a total of 10,565 records reviewed, approximately 90% were not reported.
74% were related to dogs and 70% were listed as “expected” (i.e. already listed in the product information).
The clinical severity of the reaction didn’t appear to impact whether it was reported.
Dr Heather Davies, lead author of the study, said: “As adverse drug reaction reporting rate is directly linked to the regulators ability to mitigate safety issues, this paper is a call to arms encouraging all veterinary professionals to report suspected adverse drug reactions and regulators to make reporting quicker and easier.
"It also the highlights the promise that big real-world data sets hold in enhancing drug safety monitoring processes.”
https://onlinelibrary.wiley.com/doi/full/10.1111/jsap.13721
For the study, the RVC interviewed 13 small animal general practitioners, exploring their experience of providing pre-purchase consultations for brachycephalic dogs.
The study revealed a number of barriers to delivering effective pre-purchase consultations and advice about these breeds.
They included limited time and resources, competition for appointment availability, a perception that vets are only there to fix things, public distrust of veterinary surgeons (often over money), fear of damaging vet-client relationships, and the conflicting influence of breeders and the Kennel Club on clients.
Many veterinary surgeons that took part in the research felt that they had little or no power to overcome these barriers which are highly intractable at an individual veterinarian level.
A resulting moral conflict in veterinary surgeons between their perceived ethical and moral responsibilities to animal welfare versus the needs and wants of their clients and businesses was expressed by many vets in the study, and was felt to compromise their professional integrity and autonomy.
The study set out a series of recommendations:
Dr Rowena Packer, Lecturer in Companion Animal Behaviour and Welfare Science at the RVC and lead author of the study, said: “This is the first time that the impact of brachycephaly on the practising veterinary surgeon has been explored.
"Our concerning results highlight the importance of recognising that the brachycephalic crisis is not only negatively impacting animals, but it is affecting human wellbeing too.
“Our study highlights the conflict that vets are experiencing - bound both by their duty of care to their brachycephalic patients, but also to animal welfare at a population level.
"Trying to balance both of these responsibilities in the current working environment is proving very challenging for some, leading to moral distress.
"It is, therefore, essential that we protect the mental wellbeing of vets on this issue as well as from an animal welfare perspective.
“As the brachycephalic crisis continues to prevail, the support of leading veterinary organisations is vital in providing a united voice regarding the known harms of brachycephaly and support in facilitating PPCs to ensure vets are protected, and potential owners are fully informed when it comes to acquiring decisions.”
Dr Dan O’Neill, Assoc Prof of Companion Animal Epidemiology at the RVC and co-author of the study, said:
“Over the past decade, the RVC has generated a vast evidence base revealing the true extent of the serious health issues of dogs with brachycephaly.
"This new study now focuses RVC research towards protecting the wellbeing of practising veterinary surgeons who are also shown as victims of the brachycephalic crisis.
"The clear message here is that we all need to ‘stop and think before buying a flat-faced dog’.”
There are four events: two webinars, a face-to-face event with a workshop and a presentation at this year’s BVNA Congress.
The first webinar: ‘OA pain, awareness and management: how veterinary teams can collaborate to effectively manage OA’, takes place on Thursday 7th August (7-8pm).
The second webinar: ‘Librela clinical update; 4 years of clinical experience’ is on Tuesday 19th August (7-8pm).
The face-to-face event: ‘OA pain, awareness and management: how veterinary teams can collaborate to effectively manage OA’ and ‘Librela clinical update; 4 years of clinical experience’ plus practical application workshops, is on Saturday 6th September (10am-1pm) at BVNA HQ Harlow, Essex.
Finally, the BVNA Congress presentation: ‘The Joint Approach; the importance of the nursing team in OA diagnosis and management is on Sunday 12th October (9-10am) and it is free for everyone.
Jayne Clark, Zoetis National Veterinary Manager, Pain. “We are aiming for the talks to enhance delegates’ confidence in navigating aspects of pain management in dogs and cats so that they can support pet and owners with the latest knowledge, in a highly informed, confident and objective way.”
https://bvna.org.uk/events
The company says AI Masses will allow veterinary professionals to analyse lesions suggestive of cancer in-clinic and with a fast turnaround.
The AI technology, which has been trained by human clinical pathologists, should enable individualised treatment outcomes earlier for more cases.
Zoetis says AI Masses only needs a single round of sample preparation and the results can, at additional cost, be supplemented with an expert review from a network of specialists through Zoetis’ Virtual Laboratory.
Dr. Richard Goldstein, DVM, DACVIM, DECVIM-CA, Global Chief Medical Officer at Zoetis said: “Waiting for results can be stressful for pet owners – even more so when it involves a cancer screening.
"Our research shows that up to 75% of pet owners find abnormal results highly stressful.1
"AI Masses is yet another point-of-care capability to deliver results in-clinic, further exemplifies Zoetis’ purpose to advance care for animals, shortening anxious wait times to allow for faster care decisions that help provide the best possible outcome.”
Pre-orders will be announced for US customers in Q2 2025.
VetSurgeon.org understands AI Masses will be coming to the UK some time in 2025.
https://www.zoetisdiagnostics.com
Reference
The RCVS says this is the first time that two leading organisations in veterinary QI are collaborating to establish a new evidence-based model for QI specific to veterinary care.
The project is being overseen by Jocelyn Toner MRCVS, an experienced veterinary surgeon with a background in shelter medicine and an interest in evidence-based interventions to improve welfare outcomes.
The team will test the model against a prevalent problem in practice and measure the cost of making the changes against the benefit it brings.
They will refine the model based on lessons learned before they make it available to all veterinary practices, to tackle any area a practice wants to improve, regardless of practice type or specialism.
The aim is to help time-poor practitioners implement proven QI methods to improve outcomes and provide a return on investment.
Jocelyn said: “I’m looking forward to working with colleagues from across the sector to develop a model that will make Quality Improvement more accessible, and show that it can have a real economic benefit.
"We know that there is increased demand for veterinary teams to provide more efficient and effective care while maintaining high levels of animal welfare, improving team welfare and client satisfaction.
"Over recent years an increasing number of veterinary teams have embraced QI techniques.
"Now is the time to take this to the next level by creating an evidence-based model for QI, which can be applied systematically in any veterinary setting.
The project will involve bringing together veterinary professionals to co-design the model and test it in practice.
If you are interested in supporting this work, please register your interest at: rcvsknowledge.org.uk/forms/ktp-interest-form/
In the webinar, which is sponsored by Horiba, Ian will present an update on new exotic parasite infections and distribution across the UK and Europe, and what this means for pets, livestock and the people that care for them.
“New Exotic Parasites – Worming Their Way In?” is suitable for vets, nurses, students and veterinary care assistants.
https://horiba.link/4h2.
Dr Mark Johnston, CEO of Vetstream said: “The usage data of Vetlexicon has continually shown us how important the client factsheets are to practices helping clients understand the health and welfare of their animals.
"Whilst most of our subscribers are accepting of the Vetlexicon content in English, the preferred language of many pet owners is not necessarily English, and we wanted to help practices with that.
"So a major new dimension to the new Vetlexicon website is to enable the content to be made available in many European and Asian languages so that when you are viewing a client factsheet, you can instantly see that content in Spanish, French or Korean and then print it out on paper and give to the owners for them to share with friends or family on their return to home; or to print it as a PDF and email it to them.
"Practices have told us that this will be so useful for the relationship with their clients, and so it is great to be able to provide that now.”
The company says it has also improved the interface and functionality of the site and made it mobile phone friendly.
www.vetlexicon.com
With four sessions having taken place throughout May and June this year, the autumn sessions will focus on:
RCVS Director for the Advancement of the Professions, Angharad Belcher (pictured), said: “We recognise that change cannot happen without collaboration – no one organisation can solve as complicated and multi-factorial an issue as the workforce challenge on their own.
"We hope to welcome you to these sessions to share your insights and contribute to the ongoing conversation around this important topic."
The webinars are free, last an hour and 15 minutes and count as CPD.
https://www.rcvs.org.uk/news-and-views/events/workforce-ambitions-sessions/
The RCVS VN Golden Jubilee Award is the highest individual award that can be made to a veterinary nurse.
It recognises veterinary nurses with a distinguished career, who demonstrate leadership within the profession and act as ambassadors for the value of veterinary nurses and their work.
As an RVC graduate herself, Perdi founded the UK’s first veterinary clinical skills training centre at the university, as well as developing several graduate and postgraduate veterinary nursing qualifications.
Perdi received the award for the work she did to create opportunities for nurses of diverse educational backgrounds to upskill, and for her commitment to professional development and support for nurses in practice.
Her nomination described Perdi as “an exemplary ambassador for the veterinary nursing profession, epitomising qualities that make her a beacon of inspiration and leadership. Her unwavering commitment to advancing education in veterinary nursing, particularly through the creation of the Level 6 Graduate Diploma and advanced certification programmes, showcases her dedication to raising the standards and profile of the profession.”
Perdi said: “I’m deeply honoured to receive this award, and my sincere gratitude goes to my wonderful colleagues; their encouragement has meant everything to me.
"I first started at the RVC 35 years ago, and throughout the years, I’ve had the privilege of working with dedicated and enthusiastic people across all areas of the RVC.
"Collaboration has played a key role in every step of my journey, so this recognition reflects not just my efforts, but the contributions of everyone I’ve worked with.
"I’m proud to share this honour with them all.”
All RVNs were set an email with a voting link and a unique voter code.
The College says it will be writing to the few veterinary nurses for whom it has no unique email address with further instructions.
There are 3 candidates standing this year and you can now cast your votes for up to two of them by 5pm on Friday 26 April 2024.
The candidates are:
The individual candidate profiles are available to view at www.rcvs.org.uk/vnvote24 where you can also read the candidates’ answers to two questions of their choice submitted by the profession.
The two candidates with the most votes will join VN Council for their three-year terms at the College’s AGM in July.
Any vet nurses who have not received their voting email should contact CES directly on support@cesvotes.com.
Zoetis has announced a supply problem with Equip Artervac, its vaccine against equine viral arteritis
The current inventory of Equip Artervac has an expiry date of March 29, 2023 and the company is not expecting a new batch to be available until the end of September 2023.
Zoetis says it has been working with relevant organisations to implement a plan to mitigate the impact on breeders.
The Thoroughbred Breeders Association has published advice for a blood sampling scheme at: https://www.rossdales.com/news-events/tba-members-equine-vaccine-advice-regarding-disruption-to-supply-of-equip-artervac, but Zoetis highlights that the advice requires action two weeks after the most recent EVA vaccination.
For more information contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0345 300 8034
Amanda originally studied and worked in Australia where she undertook a residency in small animal medicine at Murdoch University, completing a Masters in respiratory medicine in dogs.
She moved to the UK in 2016 to work in referral medicine, joining Hamilton Specialist Referrals in 2024 as head of its medicine service.
The webinar will include a refresher on the bacterial, fungal, parasitic and protozoal causes of lower respiratory tract disease and its pathology, after which it will look at techniques and methods for diagnosis.
Amanda's presentation will also look at the secondary effects of infectious lower respiratory disease pathogens, and prescribing and management options.
The webinar is open to vets, veterinary nurses, students and support staff.
https://horiba.link/respiratory-disease-in-dogs-and-cats
The company's teleradiology and education services are not affected, and will continue as normal.
VET.CT's CEO, Victoria Johnson said: “We are deeply sorry to have to close our teleconsulting specialist case advice service.
"Despite many loyal clients loving it and using the service to the full, wider adoption of teleconsulting has been variable globally since its launch in 2018.
"We have continued to consult, invest in, iterate and adapt the service over the past 7 years to unlock the demand.
"However, despite our efforts, we now have to take the painful and difficult decision to close our client-facing service.
"There are a multiplicity of factors that contribute to the issue and sadly, the ongoing economic pressures mean that the teleconsulting service is no longer sustainable.
"We want to reassure our clients that our quality-focused radiology reporting and education services are unaffected by these changes and continue to grow.
https://resources.vet-ct.com/statement-about-teleconsulting-service